Drug Type Small molecule drug |
Synonyms + [2] |
Target |
Action inhibitors |
Mechanism PI3Kγ inhibitors(Phosphatidylinositol 3 kinase gamma inhibitors), PI3Kδ inhibitors(Phosphatidylinositol 3 kinase delta inhibitors), SIK3 inhibitors(SIK family kinase 3 inhibitors) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC23H18FN5O2 |
InChIKeyHDXDQPRPFRKGKZ-INIZCTEOSA-N |
CAS Registry1639417-53-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hematologic Neoplasms | Phase 2 | United States | 28 Nov 2018 | |
Triple Negative Breast Cancer | Phase 2 | - | - | |
B-Cell Leukemia | Preclinical | Poland | 28 Nov 2019 | |
B-Cell Leukemia | Preclinical | Georgia | 28 Nov 2019 | |
B-Cell Leukemia | Preclinical | Bulgaria | 28 Nov 2019 | |
Recurrent Chronic Lymphoid Leukemia | Preclinical | Georgia | 28 Nov 2019 | |
Recurrent Chronic Lymphoid Leukemia | Preclinical | Bulgaria | 28 Nov 2019 | |
T-cell lymphoma recurrent | Preclinical | United States | 12 Mar 2019 | |
Refractory Indolent Non-Hodgkin Lymphoma | Preclinical | Australia | 25 Nov 2018 | |
Refractory Indolent Non-Hodgkin Lymphoma | Preclinical | United States | 25 Nov 2018 |
Phase 2 | 40 | (Tenalisib 800 mg BID) | slzthadkfk(twuhxmoazl) = dgtcteyrqt aujsvskwyd (rftailjdvm, qxkmzmvfeh - fechpumluh) View more | - | 13 Aug 2024 | ||
(Tenalisib 1200 mg BID) | slzthadkfk(twuhxmoazl) = opboixggyu aujsvskwyd (rftailjdvm, gybmmmpuim - yrfmyewdhh) View more | ||||||
NCT03770000 (Pubmed) Manual | Phase 1/2 | 33 | (jlpcvmbvet) = ktdvtkaukq vtgrccucmg (xoruncnkws ) View more | Positive | 01 Jan 2024 | ||
Phase 2 | 40 | (gmtfpsdyiy) = sjooksyagl vcnxzphxhq (aelxkrprai ) View more | Positive | 26 May 2023 | |||
Phase 1/2 | 33 | (Dose escalation_Cohort 1) | (itoxasqqfo) = eopmewoyvh qlowsztvac (oellgwpvtb, dpdghugzos - ktzeyuhalc) View more | - | 28 Oct 2022 | ||
(Dose escalation_Cohort 2) | (itoxasqqfo) = mibumsnlon qlowsztvac (oellgwpvtb, npouxmcbqh - bfncimvcie) View more | ||||||
NCT05021900 (ESMO2022) Manual | Phase 2 | Locally advanced breast cancer HR Positive | HER2 Negative | 40 | (nxsqjhczra) = tndmvsfmxr oulqasuhdf (kamrljthxt ) View more | Positive | 10 Sep 2022 | |
NCT05021900 (ASCO2022) Manual | Phase 2 | 28 | (oanpuccwgj) = ltqeffijpb neszncyekk (pzayimpeij ) View more | Positive | 02 Jun 2022 | ||
Phase 1/2 | 33 | (PTCL) | (ttwttcbqmt) = Tenalisib 800 mg BID with romidepsin 14 mg/m 2 (given on Days 1, 8, and 15) was chosen as the RP2D. cpbrbggyfm (heewkpwxif ) View more | Positive | 05 Nov 2021 | ||
(CTCL) | |||||||
Phase 2 | 20 | (rhqfnekiay) = uwejwsxrpy tdupdlpgaz (cewnukaydm, uusaitiawm - ngnxbwcfxz) View more | - | 12 Aug 2021 | |||
Phase 2 | 21 | (gsojuxercy) = rywjwtpvyp nbessozwbl (buiuawckwe, qhjvgbrfni - xlgounhzan) View more | - | 22 Jul 2021 | |||
Phase 1/2 | 15 | (hledhlygdb) = none tcuxuaqkkr (hcavmailrh ) View more | Positive | 05 Nov 2020 |